Davis R M Inc. Has $263,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Davis R M Inc. lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 14.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,645 shares of the medical equipment provider’s stock after selling 614 shares during the period. Davis R M Inc.’s holdings in Hologic were worth $263,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Covestor Ltd lifted its position in shares of Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 133 shares during the period. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Brooklyn Investment Group boosted its stake in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares in the last quarter. Empirical Finance LLC grew its holdings in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HOLX shares. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Royal Bank of Canada lowered their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Finally, Wolfe Research initiated coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Hologic presently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

HOLX stock opened at $62.59 on Wednesday. Hologic, Inc. has a 1-year low of $61.70 and a 1-year high of $84.67. The business’s 50-day moving average price is $67.87 and its two-hundred day moving average price is $75.04. The firm has a market cap of $14.04 billion, a PE ratio of 19.74, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.